These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 8450495)
1. Tissue plasminogen activator enhancing activity of vasopressin analogues in monkeys: structure-activity study. Vilhardt H; Barth T J Recept Res; 1993; 13(1-4):305-11. PubMed ID: 8450495 [TBL] [Abstract][Full Text] [Related]
2. Factor VIII and tissue plasminogen activator in monkeys after administration of DDAVP analogues. Vilhardt H; Barth T Thromb Res; 1992 Dec; 68(6):501-4. PubMed ID: 1341062 [No Abstract] [Full Text] [Related]
3. 2-O-alkyltyrosine derivatives of 1-deamino-arginine-vasopressin: highly specific and potent antidiuretic agonists. Lammek B; Bankowski K; Misicka A; Manning M; Seto J; Sawyer WH J Med Chem; 1989 Jan; 32(1):244-7. PubMed ID: 2909737 [TBL] [Abstract][Full Text] [Related]
4. Induction of uPA release in human peripheral blood lymphocytes by [deamino-Cysl,D-Arg8]-vasopressin (dDAVP). Yamaguchi Y; Yamada K; Suzuki T; Wu YP; Kita K; Takahashi S; Ichinose M; Suzuki N Am J Physiol Endocrinol Metab; 2004 Nov; 287(5):E970-6. PubMed ID: 15198931 [TBL] [Abstract][Full Text] [Related]
5. The release of factor VIII and tissue plasminogen activator can not be blocked by specific antagonists to vasopressin. Vilhardt H; Barth T J Recept Res; 1991; 11(1-4):239-45. PubMed ID: 1909360 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and some pharmacological properties of deamino(4-threonine,8-D-arginine)vasopressin and deamino(8-D-arginine)vasopressin, highly potent and specific antidiuretic peptides, and (8-D-arginine)vasopressin and deamino-arginine-vasopressin. Manning M; Balaspiri L; Moehring J; Haldar J; Sawyer WH J Med Chem; 1976 Jun; 19(6):842-5. PubMed ID: 950656 [TBL] [Abstract][Full Text] [Related]
7. Identification of plasminogen activator releasing activity in the neurohypophysis. Colucci M; Stassen JM; Salwa J; Collen D Br J Haematol; 1984 Oct; 58(2):337-46. PubMed ID: 6541053 [TBL] [Abstract][Full Text] [Related]
8. Thrombolytic therapy causes an increase in vascular permeability that is reversed by 1-deamino-8-D-vasopressin. Rudd MA; Johnstone MT; Rabbani LE; George D; Ware JA; Loscalzo J Circulation; 1991 Dec; 84(6):2568-73. PubMed ID: 1835680 [TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationship of 1-desamino-8-D-arginine vasopressin as an antiproliferative agent on human vasopressin V2 receptor-expressing cancer cells. Pastrian MB; Guzmán F; Garona J; Pifano M; Ripoll GV; Cascone O; Ciccia GN; Albericio F; Gómez DE; Alonso DF; Iannucci NB Mol Med Rep; 2014 Jun; 9(6):2568-72. PubMed ID: 24737067 [TBL] [Abstract][Full Text] [Related]
10. Glycosylated peptide hormones: pharmacological properties and conformational studies of analogues of [1-desamino,8-D-arginine]vasopressin. Kihlberg J; Ahman J; Walse B; Drakenberg T; Nilsson A; Söderberg-ahlm C; Bengtsson B; Olsson H J Med Chem; 1995 Jan; 38(1):161-9. PubMed ID: 7837227 [TBL] [Abstract][Full Text] [Related]
11. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. Cheng LL; Stoev S; Manning M; Derick S; Pena A; Mimoun MB; Guillon G J Med Chem; 2004 Apr; 47(9):2375-88. PubMed ID: 15084136 [TBL] [Abstract][Full Text] [Related]
12. DDAVP releases tPA in correlation with a fall in platelet serotonin in uraemic patients. Malyszko J; Malyszko JS; Azzadin A; Mysliwiec M; Buczko W Thromb Res; 1992 Nov; 68(3):303-8. PubMed ID: 1471076 [No Abstract] [Full Text] [Related]
13. [Experimental studies of the liberation of plasminogen activator by DDAVP]. Jablonowski C; Klöcking HP; Markwardt F Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(4):567-74. PubMed ID: 6083928 [TBL] [Abstract][Full Text] [Related]
14. DDAVP induces systemic release of urokinase-type plasminogen activator. Levi M; ten Cate JW; Dooijewaard G; Sturk A; Brommer EJ; Agnelli G Thromb Haemost; 1989 Sep; 62(2):686-9. PubMed ID: 2510348 [TBL] [Abstract][Full Text] [Related]
16. Antidiuretic activity and release of factor VIII by vasopressin analogues. Vilhardt H; Barth T; Melin P; Aurell CJ Eur J Pharmacol; 1993 Mar; 232(2-3):223-6. PubMed ID: 8467859 [TBL] [Abstract][Full Text] [Related]
17. Structural requirements of position A alpha-157 in fibrinogen for the fibrin-induced rate enhancement of the activation of plasminogen by tissue-type plasminogen activator. Schielen JG; Adams HP; Voskuilen M; Tesser GJ; Nieuwenhuizen W Biochem J; 1991 Jun; 276 ( Pt 3)(Pt 3):655-9. PubMed ID: 1905925 [TBL] [Abstract][Full Text] [Related]
18. Effects of vasopressin analogues (DDAVP, DVDAVP) in the form of sublingual tablets in central diabetes insipidus. Laczi F; Mezei G; Julesz J; Lázló FA Int J Clin Pharmacol Ther Toxicol; 1981 Feb; 19(2):63-8. PubMed ID: 7216552 [TBL] [Abstract][Full Text] [Related]
19. Impaired fibrinolytic response to DDAVP in patients with von Willebrand's disease. Sultan Y; Loyer F; Venot A Nouv Rev Fr Hematol (1978); 1992; 34(1):55-60. PubMed ID: 1523100 [TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal absorption and plasma clearance rates of [D-Arg8]vasopressin analogues in the rat. Lundin S; Folkesson HG; Pierzynovski SG; Bengtsson HI Peptides; 1994; 15(5):809-14. PubMed ID: 7984498 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]